Pfizer (NYSE:PFE) Shares Up 2.2% – Time to Buy?

Pfizer Inc. (NYSE:PFE)’s share price was up 2.2% on Thursday . The company traded as high as $26.48 and last traded at $26.17. Approximately 45,177,669 shares changed hands during trading, an increase of 10% from the average daily volume of 40,990,563 shares. The stock had previously closed at $25.60.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded the U.S. label for HYMPAVZI, widening its addressable market in hemophilia A and B and boosting confidence in Pfizer’s rare-disease franchise. Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI
• Positive Sentiment: Pfizer announced a new Phase 1 study for PF-07799544, adding another data point to its R&D pipeline and reinforcing the company’s long-term growth strategy. Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline
• Positive Sentiment: RBC Capital upgraded Pfizer to Sector Perform, saying the stock’s valuation now looks more balanced after the recent selloff and ahead of key pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Analysts and commentary pieces highlighted Pfizer’s high dividend yield and potential growth from recent acquisitions, supporting the stock’s appeal for income and value investors. This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees
• Neutral Sentiment: Some market commentary cautioned that Pfizer’s rich dividend yield may reflect lingering concerns about cash flow, debt, and long-term earnings pressure. A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
• Neutral Sentiment: Reuters reported that Pfizer’s CEO warned Germany’s drug-pricing proposals could affect future investment plans there, adding a policy overhang but not a direct near-term earnings hit. Pfizer CEO warns German investment at risk over drug pricing policies
• Negative Sentiment: Coverage emphasizing patent-cliff risk and the need to replace lost COVID-era revenue highlights why investors remain cautious about Pfizer’s medium-term growth outlook. Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion (PFE)

Analyst Ratings Changes

A number of brokerages have recently commented on PFE. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. HSBC raised their price target on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Barclays initiated coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Trading Up 2.2%

The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market capitalization of $149.15 billion, a price-to-earnings ratio of 19.98 and a beta of 0.34. The business has a fifty day moving average price of $26.52 and a 200 day moving average price of $26.32.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the firm earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PFE. Kepler Cheuvreux Suisse SA acquired a new stake in Pfizer in the 3rd quarter valued at $16,613,000. Penn Davis Mcfarland Inc. lifted its stake in shares of Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares in the last quarter. Mackenzie Financial Corp lifted its stake in shares of Pfizer by 119.6% during the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after purchasing an additional 1,691,773 shares in the last quarter. Pzena Investment Management LLC boosted its position in shares of Pfizer by 0.9% in the third quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock worth $168,565,000 after buying an additional 56,484 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in shares of Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after buying an additional 5,978,927 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.